HomeNDC LookupIngredientsHydroxyzine Hydrochloride › 16571-0114-01
HYDROXYZINE HYDROCHLORIDE 25 mg Tablet, Film Coated, 100-count — NDC 16571-0114-01 package photo

HYDROXYZINE HYDROCHLORIDE 25 mg Tablet, Film Coated, 100-count

by Rising Pharma Holdings, Inc. · 100 TABLET, FILM COATED in 1 BOTTLE (16571-114-01)
NDC 16571-0114-01
🏷️ FDA NDC (as labeled) 16571-114-01 billing pads the product segment with a zero
This package
Contains100-count Cost per ea$0.0342 NADAC Per package$3.42 / 100 tablets Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.1416/unit · Part D plans $0.1378/unit — full pricing hub ↓
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Hydroxyzine Hydrochloride (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Jun 2, 2026 — Presence of foreign substance (ANI Pharmaceuticals, Inc.) · FDA recall D-0619-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 16571-114-01
Product NDC 16571-114
11-digit billing NDC 16571011401
NCPDP billing unit EA — each (per item)
RxCUI 995218, 995258, 995281
UNII 76755771U3
Application # ANDA217652
SPL Set ID 6a1a48ac-8ad5-4363-b298-d9825ae2a448
Established class (EPC) Antihistamine
Mechanism of action Histamine Receptor Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-08-22
Route ORAL
Dosage form TABLET, FILM COATED
Substance HYDROXYZINE DIHYDROCHLORIDE
GPI-14 57200040100310
GCN Seq No 003728
GCN 13943
HICL code 001608
Ingredient (HICL) Hydroxyzine Hcl
HIC1 code Z
Therapeutic class — broad (HIC1) Body As A Whole
HIC2 code Z2
Therapeutic class — intermediate (HIC2) Antihistamines, Antiserotonins, Immunosuppressants
HIC3 code Z2P
Therapeutic class — specific (HIC3) Antihistamines - 1St Generation
AHFS code 04:04.00.00
AHFS class First Generation Antihistamines
FDB label name HYDROXYZINE HCL 25 MG TABLET
FDB brand name Hydroxyzine Hcl
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 16571-114-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 16571-0114-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Antihistamine class.

Pharmacologic class Antihistamine
Drug family (ATC) Diphenylmethane derivatives
How it works Histamine Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerRising Pharma Holdings, Inc.
Application holderGRAVITI PHARMACEUTICALS PRIVATE LTD
FDA applicationANDA217652 (ANDA)
Labeler code16571
First marketedAug 2023
Product typeHuman Prescription Drug
Portfolio525 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name HYDROXYZINE HCL 25 MG TABLET Ingredient Hydroxyzine Hcl
📖 What it is MedlinePlus · NLM

Hydroxyzine is used to relieve itching caused by allergic skin reactions, to relieve anxiety and tension, and as a sedative before and after general anesthesia for surgery. Hydroxyzine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. It also works by decreasing activity in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Hydroxyzine is most often used to relieve anxiety and tension, or to control itching from allergic conditions like hives or eczema. It's also used as a calming medication before su...
  • Drowsiness is the most common side effect — it's actually how the medication works, so some sleepiness is expected, especially when you first start. For most people it gets better...
  • This is really important to go over with your pharmacist or doctor, because hydroxyzine interacts with a number of common drugs. Combining it with alcohol, opioid pain medicines, s...
  • Can I take hydroxyzine with my other medications?
📖 Read our full Hydroxyzine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color White
ShapeRound
Imprint49
Size7 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3SY5LH9PMK
    Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
  • UNII 2S7830E561
    Crospovidone is a synthetic polymer derived from povidone. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the active ingredient can be absorbed.
  • UNII 0VUT3PMY82
    Hypromellose 2910 is a plant-derived thickening agent made from cellulose. In medicines, it forms protective coatings on tablets or capsules, controls how fast the drug releases, and thickens liquid formulations.
  • UNII 1IVH67816N
    Hypromellose 2910 is a plant-derived cellulose compound used as a thickener and film-former in medicines. It helps control how quickly the medication dissolves and creates protective coatings on tablets or capsules.
  • UNII 0WZ8WG20P6
    Hypromellose 2910 is a plant-based cellulose derivative that acts as a thickener, binder, and film-coating agent. It helps control how quickly the medicine dissolves and protects the tablet or capsule from moisture and light.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII VH2XOU12IE
    Polydextrose is a synthetic polymer made from dextrose (sugar) that acts as a bulking agent and filler in medicines. It helps give tablets and capsules proper volume and texture while often adding slight sweetness.
  • UNII 3WJQ0SDW1A
    Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII H8AV0SQX4D
    A modified starch derived from potato or corn starch. It absorbs water quickly and helps tablets or capsules break apart and dissolve in the stomach, acting as a disintegrant to ensure the medicine releases its active ingredients properly.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
  • UNII XHX3C3X673
    Triacetin is a clear, oily liquid made from glycerin and acetic acid. It works as a plasticizer and solvent in medicines, helping soften coatings and improve how liquids mix together in formulations.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

14 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.034 $3.42 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.1416 $14.16 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.1378 $13.78 / 100 tablets
Medicare Part B allowsASP · Q0177 No ASP payment limit on file for Q0177 this quarter.
NADAC price history (per ea) — tap or hover for the price & month
Feb 2024 Feb 2026 May 2026 Aug 2026 $0.044 $0.034
▼ Down 22% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🧾 Billing & reimbursement

FDA NDC (as labeled)16571-114-01
11-digit billing NDC16571-0114-01
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeQ0177
DescriptorHYDROXYZINE PAMOATE, 25 MG, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT THE TIME OF CHEMOTHERAPY TREATMENT, NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN
Billing units / pkg1 units
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Hydroxyzine Hydrochloride 25 mg 00093-5061-01 Teva 100 tablets $0.034 AB Availability likely
Hydroxyzine Hydrochloride 25 mg 00904-6617-61 Major 1 tablet $0.034 AB Discontinued
Hydroxyzine hydrochloride 25 mg 00904-7378-40 Major 500 tablets $0.034 AB Availability likely
Hydroxyzine Hydrochloride 25 mg 10702-0011-01 KVK-Tech, 100 tablets $0.034 AB Availability likely
Hydroxyzine Hydrochloride 25 mgthis 16571-0114-01 Rising 100 tablets $0.034 AB Availability likely
HydrOXYzine Hydrochloride 25 mg 16714-0082-10 Northstar 100 tablets $0.034 AB Availability likely
Hydroxyzine hydrochloride 25 mg 23155-0501-01 Heritage 100 tablets $0.034 AB Availability likely
Hydroxyzine Hydrochloride 25 mg 24658-0782-10 PURACAP 1000 tablets $0.034 AB Availability likely
Hydroxyzine Hydrochloride 25 mg 42806-0160-01 Epic 100 tablets $0.034 AB Availability likely
Hydroxyzine Hydrochloride 25 mg 59651-0500-01 Aurobindo 100 tablets $0.034 Availability likely
Hydroxyzine Hydrochloride 25 mg 60687-0675-01 American 1 tablet $0.034 AB Availability likely
Hydroxyzine Hydrochloride 25 mg 62135-0574-05 Chartwell 500 tablets $0.034 AB Availability likely
Hydroxyzine hydrochloride 25 mg 00615-8082-05 NCS 15 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 10135-0811-01 Marlex 100 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 11534-0205-01 Sunrise 100 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 31722-0501-01 Camber 100 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 43063-0518-06 PD-Rx 6 tablets FDA listed
Hydroxyzine Hydrochloride 25 mg 43063-0627-28 PD-Rx 28 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 43063-0962-01 PD-Rx 100 tablets FDA listed
Hydroxyzine hydrochloride 25 mg 45865-0675-20 Medsource 20 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 50090-2648-00 A-S 20 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 50090-3583-01 A-S 28 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 50090-5297-00 A-S 90 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 50090-6624-00 A-S 90 tablets AB FDA listed
HydrOXYzine Hydrochloride 25 mg 50090-6626-00 A-S 90 tablets AB FDA listed
HydrOXYzine Hydrochloride 25 mg 50090-6628-00 A-S 90 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-6653-01 A-S 28 tablets FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-6655-00 A-S 20 tablets FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-6657-00 A-S 90 tablets FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-6659-00 A-S 90 tablets FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-7034-00 A-S 1 tablet FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-7327-00 A-S 90 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-7329-00 A-S 90 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-7330-00 A-S 20 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-7331-00 A-S 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 50090-7332-00 A-S 30 tablets AB FDA listed
HydrOXYzine Hydrochloride 25 mg 50090-7582-01 A-S 28 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 51407-0970-10 Golden 1000 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 51655-0080-20 Northwind 20 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 51655-0589-52 Northwind 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 55154-2148-00 Cardinal 1 tablet AB FDA listed
Hydroxyzine Hydrochloride 25 mg 55154-7994-00 Cardinal 1 tablet AB Discontinued
Hydroxyzine Hydrochloride 25 mg 60760-0971-30 St. 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 60760-0990-30 St. 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 62135-0546-05 Chartwell 500 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 63187-0733-20 Proficient 20 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 63629-1856-01 Bryant 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 63629-8740-01 Bryant 100 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 65162-0671-10 Amneal 100 tablets FDA listed
Hydroxyzine hydrochloride 25 mg 67046-0713-03 Coupler 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 67046-1311-03 Coupler 30 tablets AB FDA listed
HydrOXYzine Hydrochloride 25 mg 68071-2237-02 NuCare 20 tablets AB FDA listed
HydrOXYzine Hydrochloride 25 mg 68071-3450-04 NuCare 4 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 68071-3964-03 NuCare 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 68071-4622-03 NuCare 30 tablets FDA listed
Hydroxyzine hydrochloride 25 mg 68071-5286-03 NuCare 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 68071-5296-06 NuCare 6 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 68788-7854-03 Preferred 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 68788-8707-03 Preferred 30 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 70518-1692-01 REMEDYREPACK 15 tablets AB Discontinued
Hydroxyzine Hydrochloride 25 mg 70518-1730-01 REMEDYREPACK 30 tablets Discontinued
Hydroxyzine Hydrochloride 25 mg 70518-2066-00 REMEDYREPACK 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 70518-2279-01 REMEDYREPACK 30 tablets AB Discontinued
Hydroxyzine Hydrochloride 25 mg 70518-4141-00 REMEDYREPACK 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 71205-0155-20 Proficient 20 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 71205-0273-15 Proficient 15 tablets FDA listed
Hydroxyzine Hydrochloride 25 mg 71335-0935-01 Bryant 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 71335-1047-01 Bryant 30 tablets FDA listed
Hydroxyzine hydrochloride 25 mg 71335-2340-01 Bryant 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 71335-2451-01 Bryant 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 71335-2776-01 Bryant 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 71335-3035-01 Bryant 1000 tablets AB FDA listed
HydrOXYzine Hydrochloride 25 mg 71610-0686-53 Aphena 60 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 71610-0735-30 Aphena 30 tablets FDA listed
Hydroxyzine hydrochloride 25 mg 71610-0844-53 Aphena 60 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 71610-0851-30 Aphena 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 72162-1333-02 Bryant 20 tablets FDA listed
Hydroxyzine Hydrochloride 25 mg 72162-2512-00 Bryant 1000 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 72789-0216-12 PD-Rx 12 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 76420-0882-01 Asclemed 100 tablets AB FDA listed
Hydroxyzine hydrochloride 25 mg 80425-0365-01 Advanced 30 tablets AB FDA listed
Hydroxyzine Hydrochloride 25 mg 80425-0590-01 Advanced 30 tablets AB FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Aug 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 16571-0114-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
465.9K
Units reimbursed last 4 qtrs
28.1M
Gross reimbursed last 4 qtrs
$3.98M
Avg / prescription
$8.54
Avg / unit
$0.1416
Latest quarter Q4 2025
94.4KRx
Medicaid pays / ea
$0.1416
gross reimbursed
vs
NADAC / ea
$0.0342
acquisition cost
=
Spread
+$0.1074
+314% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
40% FFS 60% MCO
Fee-for-service · 184,381 Rx Managed care · 281,531 Rx
State Medicaid map
Alaska: 67,993 units · 9,276 per 100k residents AK Maine: 494,370 units · 35,439 per 100k residents ME Washington: 1,224,952 units · 15,680 per 100k residents WA Idaho: 242,684 units · 12,357 per 100k residents ID Montana: 122,817 units · 10,850 per 100k residents MT North Dakota: 3,205 units · 409 per 100k residents ND Minnesota: 536,842 units · 9,358 per 100k residents MN Wisconsin: 501,394 units · 8,484 per 100k residents WI Michigan: 533,981 units · 5,320 per 100k residents MI New York: 1,285,941 units · 6,571 per 100k residents NY Vermont: 82,096 units · 12,689 per 100k residents VT New Hampshire: 263,081 units · 18,765 per 100k residents NH Oregon: 863,550 units · 20,400 per 100k residents OR Nevada: 460,622 units · 14,421 per 100k residents NV Wyoming: 37,509 units · 6,423 per 100k residents WY South Dakota: 51,173 units · 5,568 per 100k residents SD Iowa: 315,114 units · 9,826 per 100k residents IA Illinois: 723,283 units · 5,764 per 100k residents IL Indiana: 633,328 units · 9,229 per 100k residents IN Ohio: 996,208 units · 8,453 per 100k residents OH Pennsylvania: 1,611,851 units · 12,436 per 100k residents PA New Jersey: 261,718 units · 2,817 per 100k residents NJ Massachusetts: 241,930 units · 3,456 per 100k residents MA California: 2,803,925 units · 7,196 per 100k residents CA Utah: 248,952 units · 7,286 per 100k residents UT Colorado: 727,903 units · 12,384 per 100k residents CO Nebraska: 167,090 units · 8,447 per 100k residents NE Missouri: 1,523,540 units · 24,589 per 100k residents MO Kentucky: 786,839 units · 17,385 per 100k residents KY West Virginia: 383,410 units · 21,662 per 100k residents WV Virginia: 1,152,912 units · 13,228 per 100k residents VA Maryland: 502,732 units · 8,135 per 100k residents MD Connecticut: 177,912 units · 4,919 per 100k residents CT Rhode Island: 37,436 units · 3,419 per 100k residents RI Arizona: 972,121 units · 13,082 per 100k residents AZ New Mexico: 605,186 units · 28,628 per 100k residents NM Kansas: 243,857 units · 8,294 per 100k residents KS Arkansas: 333,450 units · 10,872 per 100k residents AR Tennessee: 581,086 units · 8,154 per 100k residents TN North Carolina: 1,103,584 units · 10,185 per 100k residents NC South Carolina: 463,204 units · 8,621 per 100k residents SC Delaware: 72,759 units · 7,057 per 100k residents DE Oklahoma: 797,941 units · 19,688 per 100k residents OK Louisiana: 614,703 units · 13,439 per 100k residents LA Mississippi: 119,987 units · 4,081 per 100k residents MS Alabama: 360,297 units · 7,054 per 100k residents AL Georgia: 542,716 units · 4,921 per 100k residents GA D.C.: 27,236 units · 4,011 per 100k residents DC Hawaii: 15,273 units · 1,064 per 100k residents HI Texas: 741,072 units · 2,430 per 100k residents TX Florida: 406,466 units · 1,798 per 100k residents FL
Units reimbursed · per 100k residents
40935,439
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Maine 35,439 /100k
2 New Mexico 28,628 /100k
3 Missouri 24,589 /100k
4 West Virginia 21,662 /100k
5 Oregon 20,400 /100k
6 Oklahoma 19,688 /100k
7 New Hampshire 18,765 /100k
8 Kentucky 17,385 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 tablets16571-0114-50 569,852 Rx · $5,643,417
100 tablets this page16571-0114-01 465,912 Rx · $3,978,664
1000 tablets16571-0114-10 403,050 Rx · $3,896,273
Drug total (last 4 qtrs): 1,438,814 Rx · 87,207,270 units · $13,518,354 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
16571-0114-01 You're viewing this 100 TABLET, FILM COATED in 1 BOTTLE (16571-114-01) $0.0342 / ea $3.42 2023-08-22 Active
16571-0114-10 1000 TABLET, FILM COATED in 1 BOTTLE (16571-114-10) $0.0342 / ea $34.17 2023-08-22 Active
16571-0114-50 500 TABLET, FILM COATED in 1 BOTTLE (16571-114-50) $0.0342 / ea $17.09 2023-08-22 Active

You're viewing the smallest of 3 pack sizes for this product.

This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.0342 NADAC).

This pack accounts for about 32% of this product's recent Medicaid fills; the largest share goes to the 500 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 16571-0114-01?
NDC 16571-0114-01 is a 100-count package — 100 tablet, film coated in 1 bottle.
What is the difference between NDC 16571-0114-01 and NDC 16571-0114-50?
Both are HYDROXYZINE HYDROCHLORIDE 25 mg Tablet, Film Coated — the drug itself is identical. NDC 16571-0114-01 is the 100-count package, while NDC 16571-0114-50 is the 500 tablets package.
What NDC number is used to bill for this package of HYDROXYZINE HYDROCHLORIDE 25 mg Tablet, Film Coated?
Bill NDC 16571-0114-01 — the 11-digit billing format is 16571011401. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 156 words

INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis.

Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies.

The physician should reassess periodically the usefulness of the drug for the individual patient.

⏱️ Dosage and Administration 165 words

DOSAGE AND ADMINISTRATION For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg for adults and 0.6 mg/kg of body weight in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all potent medication, the dosage should be adjusted according to the patient's response to therapy.

Contraindications 104 words

CONTRAINDICATIONS Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. Hydroxyzine is contraindicated in patients with a prolonged QT interval. Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range.

Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy. Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

⚠️ Warnings 29 words

WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

🤒 Adverse Reactions 134 words

ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature. Anticholinergic : Dry mouth. Central Nervous System : Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose.

Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses. Cardiac System : QT prolongation, Torsade de Pointes.

In postmarketing experience, the following additional undesirable effects have been reported: Body as a Whole : Allergic reaction. Nervous System : Headache. Psychiatric : Hallucination.

Skin and Appendages : Oral hydroxyzine is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in postmarketing reports; pruritus, rash, urticaria.

🧓 Geriatric Use 142 words

Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of hydroxyzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

🆘 Overdosage 174 words

OVERDOSAGE The most common manifestation of hydroxyzine overdosage is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.

Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action. Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes.

ECG monitoring is recommended in cases of hydroxyzine overdose. There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine.

However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

🧬 Clinical Pharmacology 130 words

CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally.

Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine's clinical effects are usually noted within 15 to 30 minutes after oral administration.

📦 How Supplied / Storage and Handling 201 words

HOW SUPPLIED Hydroxyzine Hydrochloride Tablets USP, 10 mg are available as round, film-coated, white tablets, debossed with "5" on one side and plain on the other side, containing 10 mg hydroxyzine hydrochloride, USP packaged in bottles of 100 (NDC 16571-113-01) and 500 (NDC 16571-113-50) tablets. Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as round, film-coated, white tablets, debossed with "50" on one side and plain on the other side, containing 25 mg hydroxyzine hydrochloride, USP packaged in bottles of 100 (NDC 16571-114-01), 500 (NDC 16571-114-50) and 1,000 (NDC 16571-114-10) tablets.

Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as round, film-coated, white tablets, debossed with "49" on one side and plain on the other side, containing 50 mg hydroxyzine hydrochloride, USP packaged in bottles of 100 (NDC 16571-115-01), 500 (NDC 16571-115-50) and 1,000 (NDC 16571-115-10) tablets. Dispense in a tight container as defined in the USP, with a child-resistant closure (as required). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured by: Graviti Pharmaceuticals Pvt Ltd Telangana-502307, INDIA Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Mfg.

Lic. No.: 12/SRD/TS/2017/F/G. Revised: 06/2024

📋 Description 96 words

DESCRIPTION Hydroxyzine hydrochloride, USP has the chemical name of 2-[2-[4-( p -Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride. C 21 H 27 ClN 2 O 2 . 2HCl M.W.

447.83 Hydroxyzine hydrochloride, USP occurs as a white, odorless powder which is very soluble in water. Each tablet for oral administration contains 10 mg, 25 mg, or 50 mg hydroxyzine hydrochloride, USP. Inactive ingredients include: microcrystalline cellulose, colloidal silicon dioxide, crospovidone, lactose anhydrous, sodium starch glycolate, magnesium stearate, and purified water.

Instacoat aqua III white inactive ingredients include: hypromellose, polydextrose, triacetin, polyethylene glycol, and titanium dioxide. Meets USP Dissolution Test-3. structural formula

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.